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On November  7, 2014,  Aeras  and  the  National  Institute  of  Allergy  and  Infectious  Diseases  convened  a
conference  entitled  “Vaccine  Prevention  of  Sustained  Mycobacterium  tuberculosis  Infection.”  The  purpose
of  this  meeting  was  to  explore  the  biologic  plausibility,  potential  public  health  and economic  impact,  and
regulatory  feasibility  in  attempting  to develop  a  vaccine  to prevent  sustained  infection  with  Mycobac-
terium  tuberculosis  (Mtb).  Currently  there  are  two main  goals  for tuberculosis  (TB)  vaccine  development,
to develop  a  vaccine  that could  serve  as a booster  to  Bacille  Calmette-Guérin  (BCG)  vaccination  and  pre-
vent  active  TB  in  adolescents  and  adults,  and  to develop  an improved  vaccine  to  replace  BCG  in  infants.
Although  prevention  of sustained  Mtb infection  is  being  used  as  a  proof  of biological  activity for  vaccines
in  mid-Phase  2 development,  there  currently  are  no  plans  for pursuing  a prevention  of  Mtb  infection
licensure  indication  for  TB  vaccines.  Ultimately,  pursuing  a  prevention  of  sustained  Mtb infection  indi-
cation  for TB  vaccines,  in  parallel  with  ongoing  efforts  to  develop  vaccines  to prevent  active  TB disease,
was  deemed  a potentially  important  effort,  but would  require  further  resources,  particularly  to  improve
ease  tdiagnostic  assays,  to incr
. Introduction
Dr. Lewis Schrager, Vice President, Scientiﬁc Affairs, Aeras.
ockville, Maryland, USA
Developing new vaccines for tuberculosis (TB) remains a global
ealth priority. Currently there are two main goals for TB vaccine
evelopment, to develop a vaccine that could serve as a booster
o Bacille Calmette-Guérin (BCG) vaccination and prevent active
B in adolescents and adults, and to develop an improved vac-
ine to replace BCG in infants. Although prevention of sustained
ycobacterium tuberculosis (Mtb) infection is being used as a proof
f biological activity for vaccines in mid-Phase 2 development,
here currently are no plans for pursuing a prevention of Mtb  infec-
ion licensure indication for any TB vaccines. One reason for this is
hat the biological plausibility of such an effort has been questioned
iven that, in general, vaccines do not create sterilizing immunity
Abbreviations: ADCC, antibody directed cellular cytotoxicity; AIR, Airborne
nfections Research Facility; BCG, Bacille Calmette-Guérin; CFP-10, 10 kDa cul-
ure ﬁltrate protein; CFU, colony forming units; CM,  cynomolgous macaques; CMI,
ell  mediated immunity; CT, computerized tomography; ELISA, enzyme-linked
mmunosorbant assay; ESAT-6, 6 kDa early secreted antigenic target; FDA, Food
nd Drug Administration; FDG, 18-F ﬂuorodeoxyglucose; GP, guinea pig; IFN-
,  interferon-gamma; IGRA, interferon-gamma release assay; IP-10, IFN-gamma
nducible protein 10; IU, international units; MAITs, mucosal associated invari-
nt  T-cells; MDR, multidrug-resistant; Mtb, Mycobacterium tuberculosis; NHP,
on-human primate; NTM, non-tuberculous mycobacteria; PET, positron emission
omography; PoI, prevention of Mtb  infection; QFT, QuantiFERON Gold In-Tube
nterferon gamma release assay; TB, tuberculosis; TNF-1, tumor necrosis factor-
;  TPP, target product proﬁle; TST, tuberculin skin test; VE, vaccine efﬁcacy; WHO,
orld Health Organization; XDR, extensively drug-resistant.
264-410X/$ – see front matter
ttp://dx.doi.org/10.1016/j.vaccine.2015.03.061he  regulatory  feasibility  of  this  endeavor.
and thereby prevent infection, but more often prevent disease after
a targeted microorganism has initiated infection and gone through
at least a few replication cycles. Additionally, it has been questioned
whether a vaccine to prevent Mtb  infection would actually prove to
be useful from a public health or economic perspective, as approx-
imately ninety percent of Mtb-infected individuals never develop
active TB disease. There also have been concerns as to the regulatory
feasibility of seeking a prevention of infection licensure indication
for TB vaccines, as the deﬁnitive endpoint, Mtb infection, would
be determined by the results of a diagnostic assay, rather than by
a clinical outcome as generally preferred by regulatory authori-
ties, given that Mtb  infection cannot be identiﬁed based on clinical
symptomatology.
This conference sought to address each of these issues. The ﬁrst
part of the initial session was  dedicated to deﬁning what is meant
by prevention of sustained Mtb  infection, differentiating this con-
cept from efforts to create sterilizing immunity against Mtb via
vaccination. Modeling of the likely impact of exposure intensity and
magnitude on vaccine efﬁcacy, and of the potential public health
and economic impact of vaccines capable of preventing sustained
Mtb  infection, was followed by presentations addressing the bio-
logical plausibility of this approach, with information coming from
human natural history and epidemiology studies, and from animal
models of Mtb  infection. The second session focused upon the chal-
lenges to developing improved assays to diagnose Mtb  infection,
the regulatory pathways potentially available if a prevention of sus-
tained Mtb  infection were to be pursued for a TB vaccine, and the
attributes of an optimal vaccine to prevent sustained Mtb  infection
were explored. A concluding panel discussion sought to summa-
rize the conference discussions regarding the biological plausibility,
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otential public health impact, and regulatory feasibility of pur-
uing a prevention of sustained Mtb  infection indication for a TB
accine.
. Session 1: prevention of sustained infection with
ycobacterium tuberculosis: deﬁnitions, impact and
easibility
Prevention of Sustained Mycobacterium tuberculosis Infec-
ion: Deﬁning the Term. Dr. Edward Nardell, Division of Global
ealth Equity, Brigham and Women’s Hospital, Harvard Medical
chool, Boston, Massachusetts, USA
Dr. Edward Nardell addressed the question of how best to
eﬁne “sustained Mtb  infection,” a critically important issue when
ttempting to develop vaccines for this purpose.
In contrast to the widely-held concept that infection with Mtb
s life-long, Dr. Nardell noted multiple examples of transient Mtb
nfection in humans, as reﬂected by tuberculin skin test (TST) or
nterferon-gamma release assay (IGRA) reversions [1] as well as
eversions seen in the natural transmission human-to-guinea pig
odel [2]. Laboratory exposure to aerosol delivery of 20–50 colony
orming units (CFU) of Mtb  in the highly susceptible guinea pig
odel resulted in uniform infection and death that varied by the
irulence of the strain [3]. A natural infection model in guinea
igs, however, resulted in a spectrum of outcomes including appar-
nt latency, reversions and reinfection [4]. This natural infection
odel was established in the Airborne Infections Research Facility
AIR) in South Africa, a six-bed, multidrug-resistant tuberculosis
npatient hospital ward in which 362 guinea pigs were continu-
usly exposed to patient exhaust air over a period of four months.
tb  infection was assessed with monthly serial TSTs, where the
utoff point for a positive TST was greater than or equal to six
illimeters (mm)  followed by evaluation of histological disease
rogression at necropsy. After four months, 91 (25%) of the animals
ad no evidence of infection, with 271 (75%) infected. Rever-
ion from a positive to negative TST was seen in 53 (15%) of
he animals, and was only seen in animals with a TST reaction
f less than 14 mm.  None of those animals progressed to active
isease. Thirty-three (62%) of the 53 reverted animals became re-
nfected by the end of the study due to ongoing exposure. Fifty-four
15%) of all infected guinea pigs subsequently developed active TB
isease.
The results from the AIR study are consistent with the spectrum
f possible outcomes following human Mtb  exposure [5]. These
utcomes may  be due to elimination of infection via innate immu-
ity, prior to the priming of antigen-speciﬁc T-cells; elimination
f infection in association with engagement of acquired immu-
ity and associated T-cell priming; control of infection with some
acteria persisting in non-replicating forms; bacteria replication
aintained at a subclinical level by appropriate immune responses;
nd active disease.
Dr. Nardell emphasized that much of the clinical disease
ttributed to reactivation of latent infection in high exposure sett-
ngs is likely to be due to exogenous reinfection, as shown by studies
one in the high burden settings of homeless shelters [6] and gold
ines [7]. Exogenous reinfection is an alternative pathway versus
ndogenous reactivation to cavitary TB, and continuous ongoing
ransmission, repeated exposure and reinfection in high burden
ettings represents a major obstacle to tuberculosis control [8,9].
tudies of reinfection suggest that prior TB disease is a risk fac-
or for reinfection, with recurrence rates found to be much higher
han incidence rates for new TB infections [10–12]. Accordingly,
eveloping a vaccine capable of preventing the establishment of
ustained Mtb  infection, thereby eliminating the cycle of infec-
ion leading to disease and increased susceptibility to re-infection33 (2015) 3056–3064 3057
among those who become infected with Mtb, would represent a
major contribution to Mtb  control efforts.
Vaccine Prevention of Mycobacterium tuberculosis Infection:
the Potential Impact of Exposure Intensity and Magnitude. Dr.
Steven Self, Department of Biostatistics, Vaccine and Infectious
Disease Institute, Fred Hutchinson Cancer Research Center, Uni-
versity of Washington, Seattle, Washington, USA
Dr. Steven Self discussed a mathematical modeling analysis of
the potential impact of Mtb  exposure intensity and magnitude on
vaccine efﬁcacy (VE) at the population level. While Mtb  infection
is clearly not a surrogate for active TB disease, Dr. Self noted that
it may  represent a more valid endpoint for assessing TB vaccine
biological activity than immunogenicity endpoints in the absence
of deﬁned correlates of protection from Mtb  infection or TB disease.
The determination of VE can become complicated when the vac-
cine effect is heterogeneous across the vaccinated population [13],
as is the case for TB. Not every Mtb  infection results in disease, and
it is unclear whether a vaccine developed to prevent infection with
Mtb  would protect those who would otherwise naturally advance
to active disease as opposed to those who  if infected would never
advance to active disease.
Dr. Self suggested that the effects of different levels of exposure
to the pathogen on VE at the population level may be more sub-
tle and nuanced than previously recognized. A model calibrated to
the known Mtb  infection rate in a population could provide insight
about possible vaccine-induced reduction of Mtb  transmission in
situations of differing degrees of Mtb  exposure. In this model, expo-
sure intensity and exposure magnitude are key variables that help
describe the nature of Mtb  exposure. Exposure intensity reﬂects the
number of repeated exposure events over time. Exposure magni-
tude refers to the variability of infectious potential per event, which
is related to variations in the number of droplet nuclei deposited
in the lung as well as infectious differences between Mtb  strains.
A family of curves can be generated that represent the probabil-
ity of infection with different magnitudes of exposure, depending
on a parameter that deﬁnes the probability that a single exposure
event of a certain magnitude will lead to a sustained TB infection.
This model suggests that higher levels of Mtb  exposure in a popula-
tion may  not substantially reduce the potential efﬁcacy of a vaccine
developed to prevent Mtb  infection in that population [15]. This
outcome runs counter to concerns that vaccines developed to pre-
vent Mtb  infection would be likely to have diminished effect in
populations with elevated Mtb  transmission rates, and provides
support for developing vaccines for this purpose.
Prevention of Sustained Mycobacterium tuberculosis Infec-
tion: Modeling Epidemiologic and Economic Impact. Dr. Richard
G. White, TB Modeling Group, Department of Infectious Disease
Epidemiology, London School of Hygiene and Tropical Medicine,
London, UK
What are the potential public health and economic beneﬁts of
a novel vaccine licensed for the prevention of sustained Mtb  infec-
tion? Dr. Richard White presented his review of modeling and
economic publications that addressed these questions.
Ziv et al. [14] explored the potential public health impact of pre-
and post- infection vaccines in high TB incidence countries. They
demonstrated that pre-infection vaccines that reduced suscepti-
bility to infection would more quickly reduce the number of new
infections than post-infection vaccines, while post-infection vac-
cines would be more likely to have a more rapid impact on the
reduction of TB disease. Within 30 years, however, pre-and post-
exposure vaccines may  be equally effective at reducing TB disease.
For a vaccine to contribute to global control of TB, the authors sug-
gested that both pre- and post-infection protective functions are
needed.
Dye and Williams [15] modeled the combination of diagnostics,
drugs and vaccines needed to achieve the WHO  target of TB
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limination as a public health problem by 2050. Their models
redict that an effective pre-infection vaccine would have a large
mpact, but that a post-infection vaccine or treatment that reduces
rogression to disease in latently infected individuals would be
ssential to reach the 2050 WHO  TB elimination goal.
In addressing the potential economic beneﬁts from novel TB
accines, Dr. White cited work by Bishai and Mercer [16] which
xamined the global economic beneﬁts of a novel TB vaccine with
ombined pre-and post-infection efﬁcacy, capable of reducing the
isk of Mtb  reinfection and progression to TB disease. These authors
ound that improved TB vaccines would have immediate substan-
ial ﬁnancial value to most populations in the world, with beneﬁts
o 1 billion people in prevented medical spending at a cost of $25
er vaccine dose, and a prediction of large societal beneﬁts to 3.5
illion people even at a cost of $135 per vaccine dose.
Also cited was modeling of the impact and cost-effectiveness
f new TB vaccines in low-and middle-income countries, under-
aken by Knight and colleagues [17]. Over the 2024–2050 time
orizon, vaccines targeted at adolescents and adults would have
 far greater impact on TB control than vaccines targeted at infants.
ven with relatively high vaccine prices and low efﬁcacy and short
uration, TB vaccines for adolescents and adults could be cost effec-
ive. Ditkowsky and Schwartzman [18] demonstrated that, in a very
igh burden South Africa setting, an effective pre-infection BCG
ooster vaccine would result in both societal cost savings and a
eduction in active tuberculosis cases, even at the lowest efﬁcacy
onsidered.
In conclusion, Dr. White noted that both pre-infection Mtb  vac-
ines aimed at preventing sustained Mtb  infection, and post-Mtb
nfection vaccines geared to prevent active TB disease, will be
eeded to reach the WHO  goals of elimination of TB as a public
ealth problem by 2050. Additionally, economic modeling stud-
es consistently show that improved TB vaccines would result in
ubstantial global cost savings.
Prevention of Sustained Mycobacterium tuberculosis Infec-
ion: Lessons from Human Natural History and BCG Studies. Dr.
jit Lalvani, Faculty of Medicine, National Heart and Lung Insti-
ute, Imperial College, London, UK
Natural history studies of individuals who do not develop appar-
nt infection with Mtb  despite ongoing exposure may  provide
n important opportunity to understand the factors that protect
umans from infection, and pursue these to vaccine development.
r. Ajit Lalvani focused attention on two distinct epidemiolog-
cal settings where individuals have remained uninfected. The
rst setting involves intense, sustained exposure, usually to a sin-
le tuberculosis index case, for a ﬁnite period of time (weeks
o months) e.g. within the household [19,20] or during institu-
ional outbreaks [21,22]. Here, between 30% and 60% of individuals
ecome TST positive [19,23]. The second setting involves repeated
ccupational exposure to different index cases over many years,
hich may  occur for health care workers [24]. In the latter situa-
ion, approximately 10% to 30% of exposed individuals convert to
ST positivity [25].
Dr. Lalvani described a prospective, community-based study of
hildren in Turkey that provided the ﬁrst evidence that BCG immu-
ization protects against Mtb  infection [20]. Risk factors for Mtb
nfection in 979 children from Istanbul, Turkey with household TB
ontacts were investigated using the IGRA and TST. Here, indepen-
ent risk factors for Mtb  infection were found to be an increasing
umber of index patients in the household, being the child of the
ndex patient, increasing age up to 16 years, and the absence of a
CG scar. The presence of a BCG scar, deﬁnitive evidence of past BCG
mmunization, was associated with a relative risk reduction of Mtb
nfection of 24% and a relative risk reduction of 92% for tuberculosis
isease [20]. These results represented the ﬁrst evidence that a TB
accine can provide resistance to Mtb  infection.33 (2015) 3056–3064
In a 2014 systematic review and meta-analysis of 14 studies
on the effect of BCG vaccination in children with a total of 3855
participants, BCG again was  found to protect against Mtb  infection
as well as progression from infection to disease [26]. When VE was
determined using the six highest quality studies, a VE of 27% as
detected by IGRA against Mtb  infection was found, as compared
with a VE of 71% against active TB [26]. Evidence of BCG-induced
protection, however, only was  seen in studies conducted above 40◦
latitude.
Clearance or containment of Mtb  with little or no involvement
of the adaptive immune system, either through the action of innate
immune responses occurring at the mucosal barrier or locally in the
pulmonary parenchyma, represents a type of immune response to
Mtb  exposure that may  lead to resistance to infection while main-
taining a negative IGRA response. Clearance and containment of
Mtb  infection, which may  involve transient peripheral adaptive
priming, could lead to an IGRA positive to negative reversion. In
comparison, it is through the development of a sustained Mtb  infec-
tion, accompanied by persistent peripheral adaptive priming, that
an IGRA positive, latent TB infection develops. Multiple risk factors
may  determine the outcome of exposure, including two interesting
recently implicated factors, Vitamin D levels and host genetics. Suf-
ﬁcient Vitamin D levels may  be a protective factor for Mtb  infection
[27]. Genome-wide association studies in a South African cohort
revealed a genetic locus associated with persistent TST negativity
in an endemic area [25].
Dr. Lalvani stated that, as of now, it is unclear if IGRA rever-
sion from positive to negative represents abrogation of an initial
Mtb  infection prior to its establishment. IGRA reversion typically
is associated with negative or borderline positive TST results and a
low initial IGRA response. The possibility of persistent Mtb  infection
in IGRA-reverted humans, however, cannot be ruled out. Alterna-
tive explanations of IGRA reversion may  include persistent Mtb
infection with TB-speciﬁc T-cell frequencies either at frequencies
below the level of detection (<20 per million) and/or conﬁned to
the site of latent infection. Ultimately, only long-term follow-up of
cohorts to determine the risk of progression to TB disease among
IGRA reverters will conclusively answer this important question.
Feasibility of Preventing Sustained Mycobacterium tubercu-
losis Infection: Clues from Animal Models. Dr. JoAnne Flynn,
Department of Microbiology and Molecular Genetics, University
of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Dr. JoAnne Flynn described efforts to develop new non-human
primate (NHP) models of acute Mtb  infection to more accurately
assess the feasibility of developing vaccines to prevent sustained
Mtb  infection. Most human infections result from repeated expo-
sures to very low inocula of Mtb  over time. In contrast, most vaccine
challenge studies in NHPs have utilized very high, non-physiologic
doses of Mtb, often in the range of 500–3000 CFUs, to assess the
protective effect of vaccine candidates. These overwhelming doses
provide little chance to accurately assess the ability of vaccines to
prevent either sustained Mtb  infection or TB disease.
Efforts are ongoing to develop NHP models of Mtb infection fol-
lowing low-inocula Mtb  exposure, sometimes as low as 10 CFUs
inoculated either intrabronchially via bronchoscope or through
aerosol exposure, more closely approximating physiological Mtb
exposure in humans. These models are being used both to study
the natural history of the establishment of Mtb  infection and to
serve as challenge models to assess the potential efﬁcacy of new
Mtb  vaccines. Much of this work has been done in cynomolgous
macaques (CMs), given their propensity for developing the full
range of Mtb-related outcomes seen in humans, ranging from
latency to full-blown pulmonary and extrapulmonary tuberculo-
sis [28]. Important information already has been garnered from low
dose natural history studies in CMs. One key ﬁnding was that bacte-
rial killing within individual granulomas varies widely within the
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ame host and is not seen before four weeks after infection [29].
dditionally, while granulomas are capable of killing Mtb, even in
Ms  that ultimately develop active TB, granulomas taken from CMs
hat develop sustained, latent TB infection are signiﬁcantly more
ikely to be sterile than those obtained from monkeys that devel-
ped active TB [29]. In both CMs  that developed latent infection
nd those that went on to active TB, increased numbers of sterilized
ranulomas developed over time, indicating that nearly every CM
as the ability to sterilize granulomas. The ﬁrst six weeks of infec-
ion appears to be a critical time in Mtb  infection and may  predict
he outcome of future infection and disease. Animals with latent
nfection have fewer lesions at three weeks and do not develop
ew lesions during the following three weeks [30].
Dr. Flynn described the potential for utilizing positron emission
omography (PET) in combination with computerized tomography
CT) imaging in vaccine trials to assess the events occurring in the
ung and regional lymph nodes following the administration of an
tb  challenge. Utilizing combined PET/CT imaging holds the poten-
ial of eliciting possible outcomes of an effective vaccine including
ewer granulomas established in the early phase of infection, no
issemination of granulomas, and lower overall inﬂammation as
easured by 18-F ﬂuorodeoxyglucose (FDG) avidity. She and her
ollaborators currently are testing PET/CT to assess efﬁcacy in NHP
accine trials.
Dr. Flynn’s preliminary data suggest that protection by vaccines
an result in lower inﬂammation in the lungs, with reduced dissem-
nation of early granulomas, compared to unvaccinated NHPs. Her
reviously published work indicated that CMs  administered a sub-
nit vaccine did not reactivate after anti-TNF treatment [31], and
hat this was associated with sterilized lymph nodes. Future stud-
es, with more aggressive vaccination regimens, perhaps including
n aerosol component along with an injected vaccine, may  hold
he potential for further interruption of the early events in the
stablishment of Mtb  infection.
Establishment of Mycobacterium tuberculosis Infection:
uman to Guinea Pig Natural Infection Model. Dr. Diane Ord-
ay, Assistant Professor, Mycobacteria Research Laboratory,
epartment of Microbiology, Immunology and Pathology, Col-
rado State University, Fort Collins, Colorado, USA
Most of our understanding of the initial steps in the establish-
ent of Mtb  infection come from studies in which animals are
nfected with laboratory-grown cultures of Mtb, usually through
erosol exposure or direct, bronchoscopic administration into the
ungs. In her presentation, Dr. Diane Ordway stressed that impor-
ant differences exist between these laboratory infection strategies
rom “natural infection” strategies, animal models of Mtb  infection
n which infection is allowed to occur naturally through inhalation
f ambient air laden with Mtb  derived from either human patients,
r from experimental animals, with active TB disease.
Given the importance of studying natural infection to under-
tand events occurring around the time of the establishment
f sustained Mtb  infection, efforts have been made to advance
he development of natural Mtb  infection models. Dr. Ordway
escribed one such collaborative effort to establish a human to
uinea pig (GP) model of natural Mtb  infection through the cre-
tion of the Airborne Infections Research Facility (AIR), a facility
ocated in Witbank, Mpumalanga Province, South Africa where
ir from the rooms of up to six patients with active TB disease
s circulated through an adjoining facility in which susceptible
uinea pig test animals are housed (discussed by Dr. Nardell ear-
ier in this conference). In this facility, naïve, BCG-vaccinated, and
ham-vaccinated GPs were exposed to air circulated from patients
ith drug sensitive TB, and compared to naïve, BCG-vaccinated
nd sham-vaccinated GPs exposed to circulated air from patients
ith multidrug-resistant (MDR) and extensively drug resistant
XDR) TB infections. Experiments to assess possible differences33 (2015) 3056–3064 3059
in susceptibility between animals exposed to these different Mtb
strains are ongoing [32–34].
The results of the natural infection model described by Dr. Ord-
way suggest that the establishment of sustained Mtb  infection is
achievable in the human to guinea pig natural infection model, and
holds the potential to provide important contributions in efforts
to assess TB vaccines for their ability to prevent sustained Mtb
infection. Dr. Ordway noted, however, that the full value of natural
history experiments only will come to fruition when more sensitive
tools to detect initial Mtb  infection and reinfection are developed.
Prevention of Sustained Mycobacterium tuberculosis Infec-
tion: Immunological Considerations. Dr. Joel Ernst, Director
of Infectious Disease and Immunology, New York University
School of Medicine, New York, NY, USA
Dr. Joel Ernst addressed three critical questions: (1) What are the
early events that precede the development of adaptive immunity
to Mtb  (where are the bacteria during the initial stage of Mtb  infec-
tion)? (2) Can monocytes be programmed to respond to early Mtb
infection and, if so, what are the implications of this strategy? (3)
Can human genetic studies contribute to discovering novel vaccine
strategies to prevent sustained Mtb  infection?
In the early stage of infection, mouse adoptive transfer exper-
iments of CD4+ T-cells that recognize ESAT-6 suggest that Mtb
organisms are sequestered where they are not recognized by T-cells
[35]. These experiments demonstrate that these adoptively trans-
ferred ESAT-6-speciﬁc T-cells administered one day before Mtb
challenge do not have an effect on Mtb  replication rates until after
the ﬁrst week of infection has passed, suggesting Mtb  sequestration
until that time.
Experiments were conducted to identify sites of cellular local-
ization of Mtb  in the ﬁrst fourteen days after aerosol Mtb  infection
in a mouse model. High-speed cell sorting was applied, sorting
macrophages, lung dendritic cells, recruited macrophages and neu-
trophils in an attempt to precisely localize the cellular sites of
early Mtb  sequestration. Three different Mtb infecting strains were
used; an H37Rv strain, an H37RvRD1 strain, and a Beijing 4334
strain. This investigation suggested that all three strains spread
through diverse cell types, with all initially infecting alveolar
macrophages during the ﬁrst six days of infection. By Day 14, both
the H37Rv strain and the Beijing strain predominantly infected
neutrophils, with dendritic cells and alveolar macrophages the
next most frequently infected cell types. The Beijing strain demon-
strated both particularly rapid growth from the time of initial
infection, and a more efﬁcient capability of spreading beyond alve-
olar macrophages, mainly to neutrophils but also to dendritic cells.
In contrast, the H37RvRD1 strain mostly remained within alve-
olar macrophages at 14 days post-infection. In all cases, recruited
macrophages represented the smallest proportion of cells infected
with Mtb  at 14 days post-infection.
These results suggest the need for vaccine-induced immuno-
logical intervention before natural, adaptive T-cell responses
to Mtb  develop. A challenge, however, is that the information
presented above suggests that early infection and replication
appears to be occurring in the alveoli, an immunologically pro-
tected compartment, and therefore a safe place for Mtb  growth.
Non-traditional T-cell and mucosal associated invariant T-cells
(MAITs) might have a chance to reach the alveolar compartment,
although MAITs are associated with the mucosa and therefore
may  not be capable of gaining alveolar access. Another oppor-
tunity for early, vaccine-induced immune activity is in halting
cell-to-cell mycobacterial spread. As this activity entails periods
of extracellular transit, vaccine-induced antibodies conceptually
could assist in intervening in this spread. As neutrophils appear
to play an important role in Mtb  spread, the possibility for acti-
vating bactericidal mechanisms within these cells via vaccination
merits further investigation. Finally, antibody directed cellular
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ytotoxicity (ADCC) could be important in attempting to kill Mtb
ithin the pulmonary interstitium.
Dr. Ernst also discussed the concept of “training” components of
nnate immunity, monocytes in particular, to respond more effec-
ively against Mtb  infection. Although innate immune responses
lassically are considered incapable of memory, recent investiga-
ions suggest that exposure of monocytes to pathogens, including
CG, generate epigenetic changes in the miRNA transcriptome of
onocytes that enhance monocyte function when containing ini-
ial infection [36,37]. These changes, however, are transient and
ppear to occur independently of T-cell or B-cell inﬂuence, as wit-
essed by the observation of this phenomenon in plants. Even so,
he potential for training this type of innate immune response has
een demonstrated in mice [38,39]. The possibility of manipulat-
ng this innate immune response mechanism via vaccination merits
urther exploration, particularly when attempting to abrogate the
stablishment of sustained Mtb  infection.
Human genetic studies may  provide important information that
ould contribute to development efforts for vaccines to prevent sus-
ained Mtb  infection. One study cited By Dr. Ernst was a genetic
nvestigation of individuals who did not develop TST positivity
espite living in an area hyperendemic for TB [25]. In this study,
 locus on chromosome 11 was found to be associated with non-
onversion of TST in this high-exposure area. An extension of this
tudy to household contacts of TB patients in Paris who  remained
ST negative found a large locus of 30 million to 40 million bases
ssociated with non-conversion [40]. This large locus contains two
maller loci of interest. One was the tumor necrosis factor-1 (TNF-
) locus, which controls TNF-1 release in whole blood stimulated
ith BCG. (The locus did not itself include the gene for TNF.) The
ther small locus contains the WT-1 gene, which encodes a tran-
cription factor reported to contribute to activation of the Vitamin
 receptor, and thus might play a role in modifying the response to
tb  infection.
In summary, Dr. Ernst emphasized that the early life cycle of
tb  involves transit through a series of distinct cellular niches. As
ilar lymph nodes represent a key passage point in the transit of
tb-infected, migratory dendritic cells and monocytes, it may be
ritical to develop vaccines that can exert an immunologic protec-
ive effect in the lymph nodes as well as in the lung parenchyma.
onocytes play an important role in the response to Mtb  infection
nd may  be capable of being trained to respond early in Mtb  infec-
ion, although these cells are incapable of immunological memory.
o accomplish this, tissue resident memory cells, perhaps gener-
ted through aerosol vaccine delivery, may  be needed to provide
his training. Finally, human genetic studies of persons who appar-
ntly remain uninfected with Mtb  despite ongoing exposure may
oint the way toward new vaccine strategies capable of preventing
ustained Mtb  infection.
. Session 2: challenges to developing a vaccine with a
revention of sustained Mycobacterium tuberculosis
nfection indication
Diagnosing New Mycobacterium tuberculosis Infection: Cur-
ent Challenges. Dr. Marcel Behr, Director, McGill International
B Center, Montreal, Canada.
Accurately diagnosing new infection with Mtb  represents one of
he major hurdles faced in developing a vaccine for an indication to
revent sustained Mtb  infection. Dr. Marcel Behr discussed issues
urrounding diagnosis of new Mtb  infection with either the TST or
he IGRA.
The TST was developed in 1907. Although it is still widely used,
r. Behr questioned whether this test would be approved by the
DA today. It is a complicated assay that uses a standardized but33 (2015) 3056–3064
non-synthetic reagent and displays variability due to both the
depth and angle of the needle used to inject the intradermal dose
of tuberculin antigen and to human variability in the scoring of the
resulting induration. Additionally, the TST cross-reacts with both
BCG and other non-tuberculous mycobacteria (NTM), diminishing
the speciﬁcity of a positive result.
IGRAs, in contrast, are “cleaner”, use recombinant reagents,
result in a quantitative laboratory based result, and do not cross
react with BCG, although cross reactivity has been seen with some
other NTMs. IGRAs eliminate background noise by focusing on the
detection of a single cytokine signal generated in response to 2–3
antigens. Dr. Behr suggested, however, that this simplicity of the
IGRA could also represent a problem, particularly if the test-retest
variability often seen with serial IGRA testing results from biologic
factors, such as the possibility that infected individuals change their
antigen-speciﬁc T-cell responses to Mtb  infection frequently, per-
haps even on a daily basis. Recognizing the unexplained variability
of IGRA assays, the Canadian recommendations for LTBI advise that
a TST should be used in all situations where the test is planned to be
repeated to detect new infection, for example, in the serial testing
of healthcare workers [41].
Dr. Behr raised the concern that IGRA variability in clinical trials
for prevention of sustained Mtb  infection vaccines could generate
sufﬁcient statistical noise to bias the results of an efﬁcacious vac-
cine toward the null. He did note, however, that such statistical
noise occurring in randomized clinical trials theoretically should
be randomly assigned between the comparator arms. Ultimately, it
will be important to consider whether the statistical noise inherent
in the use of IGRAs would affect the power of this and future stud-
ies, and actually bias results of an otherwise efﬁcacious vaccine to
the null.
Potential Alternative Biomarkers Useful for the Detection of
Mtb  Infection. Dr. Morten Ruhwald, Statens Serum Institute,
Copenhagen, Denmark.
Dr. Morten Ruhwald described progress in the development of
the next generation of IGRAs, which promise to reduce assay vari-
ability while also making the assays simpler and cheaper to use. In
the currently licensed IGRAs, the patient blood sample containing
T-cells and antigen presenting cells is combined with Mtb-speciﬁc
antigens: peptides derived from the ESAT-6, CFP-10 and TB7.7 pro-
teins. The tube is incubated to allow the Mtb  antigens to drive the
immune response and the T-cell generated IFN- is then quanti-
tated using a detection assay. A diagnostic algorithm is applied to
determine the cutoff point between a positive and negative result.
Dr. Ruhwald discussed opportunities to improve the IGRA
assay by identifying additional Mtb  speciﬁc antigens and alter-
native immunodiagnostic markers to IFN-. The proinﬂammatory
chemokine IP-10 (IFN- inducible protein 10, also known as
CXCL10) is secreted by monocytes in response to a number of T-
cell derived signals including IFN- [42]. In contrast to cytokines
like IFN-, which are secreted at very low concentrations to direct
immunological responses from cells in the immediate area of the
cytokine release, chemokines like IP-10 are intended to have an
effect over larger distances, and therefore are expressed at much
higher levels. IP-10 is expressed at 100 fold higher levels than IFN-.
This level of expression dramatically reduces analytical variability
in assays incorporating IP-10 as a diagnostic indicator. Importantly,
this higher expression level also permits the use of simpler diagnos-
tic techniques that may be more accessible in low resource settings,
such as utilizing dried blood spots [43], a rapid lateral ﬂow test [44]
and RT-qPCR assays [45]. More than 29 diagnostic accuracy stud-
ies have demonstrated that IP-10 and IFN- responses are at least
comparable in speciﬁcity and sensitivity (reviewed in [46,47]).
The identiﬁcation of new Mtb  antigens to drive IFN- and IP-
10 release has the potential to improve the sensitivity of IGRAs
[48] and may  also identify new antigens for vaccine development.
ccine 
D
e
a
d
c
T
a
t
w
a
M
d
o
a
t
T
w
c
T
c
I
p
i
s
t
v
M
R
P
C
A
w
T
s
c
s
e
s
b
a
i
a
s
f
o
t
p
t
t
u
r
o
o
a
s
o
s
w
c
d
tConference report / Va
evelopment of IGRAs utilizing different Mtb  antigens also is nec-
ssary to test new vaccines that include ESAT-6, CFP10 or TB7.7
ntigens. Such vaccines cannot use currently available IGRAs to
etermine Mtb  infection because the antigens contained in the vac-
ines themselves, not Mtb  exposure, would prime antigen speciﬁc
-cells and create false positive results.
The current effort to assess the H56:IC31 TB vaccine represents
n example of this challenge. The H56:IC31 vaccine is a fusion pro-
ein of three Mtb  antigens, ESAT-6, Ag85b and Rv2660c, combined
ith the adjuvant IC31. Because of the presence of the ESAT-6
ntigen, studies to assess the efﬁcacy of the vaccine to prevent
tb  infection in humans will require development of an IGRA that
oes not contain this antigen. Dr. Ruhwald described the process
f creating an ESAT-6-free IGRA assay, which began with the single
ntigen screening of 10 potential Mtb  antigens not found in BCG in
hree geographically diverse sites: Egypt, Greenland and Denmark.
hree of the most potent antigens for IFN- release, QCT 6, 7 and 13,
ere combined with CFP10 to produce an ESAT-6-free IGRA antigen
ocktail that now has been validated in studies in Egypt/Denmark,
anzania and South Africa. In all cases, this ESAT-6-free IGRA had
omparable accuracy to the conventional IGRA assay using either
FN- or IP-10 as the immunologic diagnostic readout.
The ability to accurately assess new Mtb  infection is critical to
otential regulatory approval of Mtb  vaccines for a prevention of
nfection indication. Accordingly, the development of better, more
ensitive assays, including improved IGRAs, to detect Mtb  infec-
ion must be included in any comprehensive plan to develop Mtb
accines for this indication.
Regulatory Implications of Seeking a Prevention of Sustained
ycobacterium tuberculosis Infection Indication. Dr. Roshan
amanthan, Medical Ofﬁcer, Division of Vaccines and Related
roduct Applications, Ofﬁce of Vaccine Research and Review,
enter for Biologics Evaluation and Research, US Food and Drug
dministration, Silver Spring, Maryland, USA
Dr. Roshan Ramanathan discussed the laws and regulatory path-
ays applicable to the clinical development of an Mtb vaccine.
he United States FDA licenses vaccines that have been demon-
trated to be safe and effective, and that are manufactured in a
onsistent manner [49]. All indications must be supported by sub-
tantial evidence of effectiveness with the expectation that this
vidence is derived from adequate and well-controlled clinical
tudies [50]. Dr. Ramanathan described two pathways applica-
le to licensure of vaccines: traditional approval and accelerated
pproval [51]. For traditional approval, evidence of effectiveness
s based on protection against clinical disease or, in certain cases,
n immunologic response. An immunologic response marker may
upport traditional approval of a vaccine if it predicts protection
rom disease and can be reliably measured in a validated assay. Use
f an immunologic marker is facilitated by an understanding of
he disease pathogenesis and the mechanism by which the vaccine
revents disease.
The accelerated approval pathway permits approval of vaccines
o prevent serious or life-threatening diseases or conditions and
hat provide a meaningful beneﬁt over existing therapies. Approval
nder this pathway is based on the effect of the vaccine upon a sur-
ogate endpoint that is reasonably likely to predict clinical beneﬁt
r on the basis of an effect on a clinical endpoint other than survival
r irreversible morbidity. A surrogate endpoint is a marker, such
s a laboratory measurement, radiographic image or other mea-
ure thought to predict clinical beneﬁt but is not itself a measure
f clinical beneﬁt. Adequate data supporting the use of the chosen
urrogate marker are required. Licensure of a vaccine via this path-
ay requires that adequate and well-controlled studies conﬁrm
linical beneﬁt. Conﬁrmatory studies must be conducted with due
iligence and are often underway at the time the applicant submits
he marketing application to the FDA.33 (2015) 3056–3064 3061
Regardless of the pathway pursued, a critical issue with respect
to the development of a vaccine to protect against sustained and/or
latent Mtb  infection is that only 10% of those with sustained or
latent Mtb  infection will develop active TB disease. The applicant
would need to provide a compelling argument that this indication
is clinically meaningful, and that the vaccine is likely to prevent
disease in the targeted population.
Dr. Ramanathan emphasized that regulatory pathways to licen-
sure for TB vaccines are available. Given the complexities of
regulatory issues concerning the development of a vaccine for pre-
vention of sustained Mtb  infection, Dr. Ramanathan encouraged
developers to engage with the FDA early in vaccine develop-
ment so that the Agency may provide feedback on the clinical
development plans for speciﬁc products. Engagement of regu-
latory authorities, manufacturers and the scientiﬁc community
will be necessary in order to develop a safe and effective TB
vaccine.
Design Challenges for Prevention of Sustained Mycobac-
terium tuberculosis Infection Trials. Dr. Ruth Ellis, Director of
Clinical Development, Aeras, Rockville, MD,  USA
Dr. Ruth Ellis described the rationale for and design of the ﬁrst
trial of a TB vaccine with a primary prevention of Mtb  infection
(PoI) endpoint, a phase 2 proof-of-concept clinical trial now under-
way in a South African adolescent population at high risk for Mtb
infection (ClinicalTrials.gov Identiﬁer: NCT 02075203). In her pre-
sentation, Dr. Ellis also highlighted the challenges in designing
studies attempting to assess vaccine efﬁcacy in preventing de novo
Mtb  infection.
A vaccine that prevents Mtb  infection may be able to inter-
rupt the cycle of disease and transmission, potentially leading to
a large reduction in TB incidence at the population level. Addition-
ally, a clinical trial with an endpoint of Mtb infection, in contrast
to an endpoint of TB disease, will inherently require fewer subjects
and a shorter time frame to produce statistically signiﬁcant results.
Accordingly, a phase 2 PoI trial represents an important strategic
step in the development pathway of a TB vaccine candidate, as it
offers the potential of identifying a biological signal of potential
efﬁcacy, one that can provide the conﬁdence needed by vaccine
developers to commit the extensive resources required to conduct
late phase 2 and phase 3 licensure studies. Obtaining a biological
signal of potential efﬁcacy is particularly important in the effort to
develop a TB vaccine given the absence of an immune correlate of
protection to guide these efforts.
A major challenge in designing and conducting a PoI study is
to select an assay with sufﬁcient reliability to accurately iden-
tify new Mtb  infections. In the trial described by Dr. Ellis, the
QuantiFERON®-TB Gold In-Tube (QFT) IGRA was  selected to iden-
tify new Mtb  infections among participants. A challenge in using
the QFT IGRA is the numerous sources of variability in this assay
[52]. Additionally, a valid conversion cutoff point continues to be
unclear. Also unclear is whether reversion from a positive to a
negative result reﬂects a true biologic event or simply assay vari-
ability. The TST could not be used to identify new Mtb infection
in this trial because of its lack of speciﬁcity in BCG vaccinated
populations.
Another major challenge in designing and conducting a PoI trial
is to identify a population with a high enough incidence of Mtb
infection to make the trial feasible to conduct in a stringent bud-
getary environment. The PoI trial described by Dr. Ellis is being
conducted in a population of 990 healthy, HIV uninfected, remotely
BCG vaccinated and QFT negative adolescents aged 12–17 in the
Western Cape area of South Africa, where annual rates of conver-
sion to a positive QFT test are 14% [53], and QFT positivity and
conversion is associated with an eight-fold higher risk of progres-
sion to TB disease within 2 years when compared to nonconverters
[54]. It is this extraordinarily high incidence of Mtb  infection, in
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ombination with relaxed conﬁdence intervals around a targeted
accine efﬁcacy of 50%, appropriate for a phase 2 proof-of-concept
tudy, that permits a sample size of fewer than 1000 to be enrolled
330 per group).
The study is partially blinded and subjects are randomized 1:1:1
o receive vaccination with H4:IC31 (Aeras 404: a fusion peptide
accine developed by the Statens Serum Institute, Sanoﬁ Pasteur
nd Aeras consisting of Mtb  antigens 85B and TB 10.4 and adju-
anted with the proprietary adjuvant IC31, developed by Valneva),
CG revaccination, or placebo on Day 0. QFT assays performed at 3
onths (Day 84) allow a washout point for QFT positive subjects
ho were infected around the time of the initial screening but were
ot detected because measurable cellular responses of Mtb  infec-
ion were not yet evident. QFT assays are repeated at 6, 12, 18,
nd 24 months. Individuals who become QFT positive are followed
p at 3 and 6 months after the conversion event to determine if
eversion to a QFT-negative state occurs. The primary endpoint of
he trial is to evaluate prevention of Mtb  infection by rates of ini-
ial QFT conversion. The secondary endpoint is to measure rates of
ustained QFT conversion. In both cases, the effect of Aeras 404
nd BCG revaccination will be compared to placebo. Additional
xploratory objectives of the trial include the effect of applying
lternative conversion cut-off points to rates of QFT conversion and
eversion.
Aeras plans to implement additional PoI trials in an effort to
fﬁciently obtain biological signals of potential efﬁcacy for other
B vaccine candidates that will increase the likelihood of vaccine
uccess in later stage trials. If vaccine licensure is sought for a pre-
ention of Mtb  infection indication, it will be important to improve
he sensitivity of the IGRA assay, or develop a new, more sensi-
ive and less variable assay to reliably detect new Mtb  infection, to
rovide regulatory authorities the degree of conﬁdence required to
erit licensure.
Selecting Vaccine Candidate Attributes Optimal for Preven-
ing Sustained Mtb  Infection. Dr. Barry Walker, Vice President,
reclinical Development, Aeras, Rockville, Maryland, USA.
Dr. Barry Walker noted that either clearance of Mtb  or blocking
urther replication of the organism may  be functionally equivalent
o preventing sustained infection. A vaccine being developed for a
revention of sustained Mtb  infection indication has the opportu-
ity to interdict establishment of infection at a number of points in
he earliest stages of infection, from the initial encounter with the
rganism at the mucosa, through the ultimate formation of granu-
omas. This implies that a polyfunctional vaccine strategy, targeting
ore than one point of potential susceptibility of Mtb  to immuno-
ogical activity, may  have the greatest opportunity to achieve this
oal.
Dr. Walker listed ﬁve potential points leading to the estab-
ishment of sustained Mtb  infection where a vaccine could have
n effect: (1) at or around the initial invasion through the lung
ucosa; (2) during phagocytosis into alveolar macrophages; (3)
uring replication within alveolar macrophages; (4) at the estab-
ishment of the primary Ghon focus and (5) during the period
f regional dissemination and establishment of secondary foci,
ainly within pulmonary granulomas. For a vaccine regimen to
uccessfully interdict at the pulmonary mucosa or at the time
f phagocytosis, some combination of vaccine-mediated physio-
ogical modulation of the mucosa, particularly the development
f mucosal antibodies, in combination with systemic antibody
roduction, an ADCC response, innate immunity stimulation, and
tb-speciﬁc cell mediated immunity (CMI) development would
eem optimal. The potential for priming tissue effector memory
hich could provide a rapid, direct, parenchymal-based response
o Mtb  infection and also potentially signal local innate responses
o function at maximum efﬁciency is an area of particular research
nterest. The possibility of priming intra-luminal macrophages in33 (2015) 3056–3064
addition to interstitial macrophages to respond to Mtb  infection
also should be explored.
A vaccine regimen targeting the downstream steps leading to
establishment of sustained Mtb  infection, including the develop-
ment of the primary Ghon focus and the process of stimulating
granuloma formation, would most likely rely on a robust CMI
response either alone or in combination with innate immunity
stimulation, prompted either by the vaccine itself or by novel
adjuvants administered along with the vaccine. Targeted patho-
physiological mechanisms may  include macrophage functions,
T-cell homing, accentuated macrophage killing of phagocytosed
bacteria, or direct killing of infected macrophages along with the
internalized mycobacteria.
When developing a vaccine aimed at prevention of sustained
mycobacterial infection, Dr. Walker cautioned that the target
produce proﬁle (TPP) should be carefully spelled out prior to
proceeding with product development. Components of the TPP that
should be clear as development proceeds include the target popula-
tion (e.g., adolescents/adults, infants, HIV-infected or–uninfected);
the speciﬁc endpoint being assessed as this will likely become the
indication for which marketing approval will be sought; the mech-
anism of vaccine action and the nature of vaccine administration
(e.g., injection, aerosol).
Ultimately, a combination of vaccines using different platforms
expressing the same set of genes, or different vaccines altogether
(e.g., a vectored subunit vaccine in combination with a whole
mycobacteria cell vaccine), perhaps administered in different ways,
e.g., one via aerosol and one via injection, may  be required to pre-
vent sustained Mtb  infection. Clearly a robust means to assess the
potential efﬁcacy of these various vaccine strategies in the preclin-
ical space will be critical in identifying the most promising vaccines
and vaccination regimens to take to the clinic.
4. Session 3: panel discussion: the path forward to a
vaccine indicated for the prevention of sustained
Mycobacterium tuberculosis infection
Panel Chair: Dr. Dan Hoft, Department of Molecular Microbi-
ology and Immunology, St. Louis University.
Panelists
Dr. Marcel Behr
Dr. Mark Hatherill, Director, South African Tuberculosis Vac-
cine Initiative, University of Cape Town, South Africa
Dr. Helen McShane, Professor of Vaccinology, Nufﬁeld Depart-
ment of Medicine, Oxford University, UK
Dr. Larry Schlesinger, Chair, Department of Microbial Infection
and Immunity, Wexner Medical Center, Ohio State University,
Columbus, Ohio, USA8
Dr. Christine Sizemore, Chief, TB, Leprosy and Other Mycobac-
terial Diseases Section, Division of Microbiology and Infectious
Diseases, NIAID, NIH, Bethesda Maryland, USA
Dr. Tom Evans, CEO, Aeras, Rockville, Maryland, USA.
Addressing the challenges inherent in interpreting IGRA results,
particularly in cases of IGRA reversion, was  highlighted as a major
need by the panel. Currently, it cannot be determined with conﬁ-
dence whether a person who  demonstrates a transiently positive
IGRA result was infected with Mtb  and then cleared it, or whether
such a result represents vagaries in the assay. Clarifying this
situation would represent an important contribution to efforts
attempting to assess TB vaccines for their ability to prevent sus-
tained Mtb  infection.
The panel summarized the perspectives derived from the con-
ference speakers concerning the type of immunological activity
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hat a vaccine likely would need to stimulate to prevent sustained
tb  infection. A successful vaccine likely would need to induce
egional tissue immunity, particularly in the lung; lead to a rapid
esponse to repeated low-level challenge from inhaled environ-
ental Mtb  organisms; induce both antibodies and conventional
-cells; and induce unconventional T-cell responses.
The panel noted that the information presented during this
onference suggested that developing vaccines for a prevention
f sustained Mtb  infection indication would have both a public
ealth and economic value, and potentially would be feasible from
 regulatory standpoint. Additionally, developing vaccines for this
ndication appeared to be biologically plausible. Based on the infor-
ation presented in this conference, it also seemed clear that the
B vaccine development ﬁeld was asking the right questions about
otential pathways for vaccine development. Given the importance
f pulmonary-based immune responses in attempting to prevent
ustained Mtb  infection, it was recommended that every TB vac-
ine development pathway include studies in which the pulmonary
mmune response to the vaccine under investigation be assessed
ith specimens obtained via bronchioalveolar lavage. Secondary
actors, such as diabetes or underlying lung pathology caused by
nvironmental lung disease and occupational exposure to smoke,
lso must be considered when assessing vaccine efﬁcacy to pre-
ent sustained Mtb  infection. Additionally, it was noted that twenty
ercent of TB disease is extrapulmonary, resulting in a need to
evelop better assays for detecting extrapulmonary TB. The need
o develop more sensitive means of identifying Mtb  infection also
as stressed, to assess the efﬁcacy of vaccines to prevent both sus-
ained, de novo Mtb  infection and Mtb  reinfection among those
ho have been cured of initial TB disease.
The panel emphasized the need to utilize advanced immunolog-
cal assessment technologies, such as transcriptomics, in both the
ung and periphery of non-human primates and humans, to more
ccurately bridge assessments of vaccine activity. This approach
ould serve to help de-risk the resource commitment required for
ater-stage development of TB vaccine candidates.
While there was agreement that developing vaccines to prevent
ctive TB disease would remain the major focus of the TB vaccine
evelopment ﬁeld, the panel concluded that there did not appear
o be biological, public health, economic, or absolute regulatory
onstraints against developing vaccines to prevent sustained Mtb
nfection, particularly if improvements were made in our ability to
iagnose Mtb  infection in a more sensitive and reliable fashion.
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